Research peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-05. Anything still debated is marked as such rather than presented as settled.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
== History == "During the 17th and 18th centuries, various forms of immunotherapy in cancer became widespread... In the 18th and 19th centuries, septic dressings enclosing ulcerative tumours were used for the treatment of cancer. Surgical wounds were left open to facilitate the development of infection, and purulent sores were created deliberately... One of the most well-known effects of microorganisms on ... cancer was reported in 1891, when an American surgeon, William Coley, inoculated patients having inoperable tumours with [ Streptococcus pyogenes ]." "Coley thoroughly reviewed the literature available at that time and found 38 reports of cancer patients with accidental or iatrogenic feverish erysipelas. In 12 patients, the sarcoma or carcinoma had completely disappeared; the others had substantially improved. Coley decided to attempt the therapeutic use of iatrogenic erysipelas..." "Coley developed a toxin that contained heat-killed bacteria [ Streptococcus pyogenes and Serratia marcescens ]. Until 1963, this treatment was used for the treatment of sarcomas." "Coley injected more than 1000 cancer patients with bacteria or bacterial products." "51.9% of [Coley's] patients with inoperable soft-tissue sarcomas showed complete tumour regression and survived for more than 5 years, and 21.2% of the patients had no clinical evidence of tumour at least 20 years after this treatment..." Research continued in the 20th century under Maria O'Connor Hornung at Tulane Medical School.
The Culture is a fictional interstellar post-scarcity society created by the Scottish writer Iain M. Banks and features in a number of his space opera novels and works of short fiction, collectively called the Culture series. The Culture is composed primarily of humanoid aliens, artificial intelligences (A.I.), and a number of other sentient life forms. The A.I. intelligence covers a spectrum; simple programs performing a specific function (e.g. controlling spacesuits), human-equivalent drones and hyper-intelligent Minds who organise and oversee the society. Beyond scarcity, the Culture has no need for money; instead, Minds organise society to maximise the well-being of its citizenry. The protagonists, almost always humanoids, are generally those who have chosen to work for the Culture's diplomatic or espionage organs and interact with other civilisations whose citizens act under different ideologies, morals, and technologies. The Culture generally has more advanced technology relative to most other civilisations it shares the galaxy with. Most of the Culture's citizens do not live on planets but in artificial habitats such as orbitals and ships, the largest of which are home to billions of individuals. The Culture's citizens have been genetically enhanced to live for as long as they desire and have modified mental control over their physiology, including the ability to introduce a variety of psychoactive drugs into their systems, change biological sex, or switch off pain at will.
=== Oceania === The white shark population is estimated to be 2,500–6,750 individuals around eastern Australia and New Zealand. In 1999, the Australian Government gave legal protection to the species under the Environmental Protection and Biodiversity Conservation (EPBC) Act, subsequently declaring it vulnerable in 2000. Similar protections exist at the state level—some predating federal law—with New South Wales, Tasmania, and Western Australia listing the species as vulnerable, and Victoria classifying it as endangered. To bolster these protections, the federal government launched the White Shark Recovery Plan in 2002 to mandate conservation research and regulate shark-related trade and tourism. An updated 2013 recovery plan reported moderate success, with 14 of its 34 original objectives completed. A study in 2012 found that Australia's white shark population is separated by the Bass Strait into genetically distinct eastern and western populations, necessitating regionalized conservation strategies. Population declines prior to protection were driven by commercial and sport fishing, along with entanglement in beach protection netting. By 2013, incidental deaths from commercial and recreational fishing had decreased, yet the population had not fully recovered. Despite federal protections, white sharks are still killed in state-run "shark control" programs (shark culling) intended to reduce attacks. Queensland and New South Wales continue to use nets and traps, which contribute to declining numbers in eastern Australia.
=== Animals === Animals have senses, are able to move, and have physical appetites. Apex predators like the lion could move vigorously, and has powerful senses like keen eyesight and the ability to smell their prey from a distance, while a lower order of animals might wiggle or crawl, or like oysters were sessile, attached to the sea-bed. All, however, share the senses of touch and taste.
William Turner's Historia Avium (History of Birds), published at Cologne in 1544, was an early ornithological work from England. He noted the commonness of kites in English cities where they snatched food out of the hands of children. He included folk beliefs such as those of anglers. Anglers believed that the osprey emptied their fishponds and would kill them, mixing the flesh of the osprey into their fish bait. Turner's work reflected the violent times in which he lived, and stands in contrast to later works such as Gilbert White's 1789 The Natural History and Antiquities of Selborne which were written in a tranquil era. In the 17th century, Francis Willughby (1635–1672) and John Ray (1627–1705) created the first major system of bird classification that was based on function and morphology rather than on form or behaviour. Willughby's Ornithologiae libri tres (1676) completed by John Ray is sometimes considered to mark the beginning of scientific ornithology. Ray also worked on Ornithologia, which was published posthumously in 1713 as Synopsis methodica avium et piscium. The earliest list of British birds, Pinax Rerum Naturalium Britannicarum, was written by Christopher Merrett in 1667, but authors such as John Ray considered it of little value. Ray did, however, value the expertise of the naturalist Sir Thomas Browne (1605–1682), who not only answered his queries on ornithological identification and nomenclature, but also those of Willoughby and Merrett in letter correspondence.
Sources: en.wikipedia.org
Chemical intervention-related results First senolytics discovered using artificial intelligence: Teams from the University of Edinburgh and the Massachusetts Institute of Technology independently report the discovery of senolytics using artificial intelligence for screening large chemical libraries. The works reported compounds of comparable efficacy and increased potency than other known senolytics. A study identifies low levels of taurine, which declines with age, as a driver of the aging process and suggests that taurine supplements may increase lifespan. Ora Biomedical announces the "million molecule challenge", an effort to assess 1 million potential longevity interventions within five years using artificial intelligence. A study suggests chemical alternatives to age reversal via Yamanaka factors gene therapy are feasible via early in vitro fibroblasts data. These results have not yet been validated in an animal and via more reliable "improvements in age-related health metrics or lifespan". Subcutaneous administration of longevity factor α-klotho enhanced cognition in old rhesus macaques. In a paywalled review, the authors of a heavily cited paper on the hallmarks of aging update the set of proposed hallmarks after a decade. A review with overlapping authors merge or link various hallmarks of cancer with those of aging. A study concludes that retroviruses in the human genomes can become awakened from dormant states and, in senescent cells and aged tissue, contribute to aging which can be blocked by neutralizing antibodies, resulting in improved function.
=== Hari Dhar === Hari Dhar (Nabhaan Rizwan) is a new grad assigned to Pierpoint's IBD desk alongside Gus. Having come from a family of Indian immigrants and graduated from a state school, Hari feels out of place among Pierpoint's new grads, and overcompensates by working through the night at the office, sleeping in the bathrooms, skipping nights out with his colleagues, and abusing energy drinks and stimulant pills to stay awake. Within days, Hari dies of a heart attack in Pierpoint's bathroom stalls. Pierpoint does brief damage control before going back to business as usual. However, Hari's death causes many Pierpoint employees to reflect on the cutthroat culture of investment banking, and plays a role in Gus' eventual decision to leave the firm.
Phase two of the plan, known as "Opportunity", began in July 2019 and called for the creation of programs and initiatives to prevent youths predisposed to crime from engaging in criminal activity. The programs and initiatives included creating scholarships, building schools and sports centers, and improving healthcare. Bukele established the Social Fabric Revitalization Unit to implement the phase. Phase three, known as "Modernization", began in August 2019 and called for the improvement of equipment used by the country's security forces; it included issuing new weapons, gear, helicopters, and drones to the security forces. Phase four, known as "Incursion", began in July 2021 when the security forces began patrolling areas with a high gang presence that were considered difficult to access. Phase five, known as "extraction", began in November 2022. Security forces were ordered to "surround large cities and extract the terrorists [gang members] who [were] hiding within the communities, without giving them the slightest possibility of escape". Phase six, known as "integration", began in September 2023, when Bukele established the National Integration Directory to combat poverty and unemployment. Details about phase seven, which has not yet been implemented, are not publicly known. El Salvador's homicide rate has decreased every year of Bukele's presidency, a downward trend that began in 2016.
=== Analysis === Greg Raymond of the Australian National University wrote a fortnight after the vote that the outcome reflected a political system built on patronage and on accommodation with the palace, and that Bhumjaithai's move from coalition broker to governing party made structural reform unlikely. He traced Anutin's political education to Newin Chidchob, the Buriram politician who founded Bhumjaithai and who in 2008 delivered the bloc of votes that made Abhisit Vejjajiva prime minister. Raymond expected the coalition to survive a full term while constitutional change stalled, noting that the referendum held alongside the election was only the first of three required and that any draft would still need the support of a conservative Senate. He also observed that allegations of irregularities had left the Election Commission facing public scepticism, and that the result coincided with the release of Transparency International's 2025 Corruption Perceptions Index, which placed Thailand below Laos and Vietnam.
Transuranic waste (TRUW) as defined by U.S. regulations is, without regard to form or origin, waste that is contaminated with alpha-emitting transuranic radionuclides with half-lives greater than 20 years and concentrations greater than 100 nCi/g (3.7 MBq/kg), excluding high-level waste. Elements that have an atomic number greater than uranium are called transuranic ("beyond uranium"). Because of their long half-lives, TRUW is disposed of more cautiously than either low- or intermediate-level waste. In the United States, it arises mainly from nuclear weapons production, and consists of clothing, tools, rags, residues, debris, and other items contaminated with small amounts of radioactive elements (mainly plutonium). Under U.S. law, transuranic waste is further categorized into "contact-handled" (CH) and "remote-handled" (RH) on the basis of the radiation dose rate measured at the surface of the waste container. CH TRUW has a surface dose rate not greater than 200 mrem per hour (2 mSv/h), whereas RH TRUW has a surface dose rate of 200 mrem/h (2 mSv/h) or greater. CH TRUW does not have the very high radioactivity of high-level waste, nor its high heat generation, but RH TRUW can be highly radioactive, with surface dose rates up to 1,000,000 mrem/h (10,000 mSv/h). The United States currently disposes of TRUW generated from military facilities at the Waste Isolation Pilot Plant (WIPP) in a deep salt formation in New Mexico.
Sources: en.wikipedia.org
Cannabinoid receptor 1 (CB1) is colocalized on orexinergic projection neurons in the lateral hypothalamus and many output structures, where the CB1 and orexin receptor 1 (OX1) receptors physically and functionally join to form the CB1–OX1 receptor heterodimer. There is substantial anatomical and functional overlap and systemic cross-talk between the endocannabinoid system and orexin system within the central nervous system.
By the end of August 1944 the German forces in Italy had formed the Gothic Line along the Apennine Mountains, and the 6th Division had come under the command of the US Fifth Army. The difficulty of using tanks in the mountains led to the Rhodesians of Prince Alfred's Guard temporarily adopting an infantry role, using dismounted tank machine-guns to support the Natal Carabineers during the fighting for Pistoia during early September. The Southern Rhodesian Anti-Tank Battery meanwhile converted partially from guns to 4.2-inch mortars. The South Africans and Rhodesians met with fierce resistance from the 16th SS Panzer Grenadier Division, but helped push the Germans northwards towards the Reno river. Hoping to repel Allied advances towards Bologna, the Germans took up positions on Monte Stanco overlooking the main roads towards the city. Two Allied assaults on the mountain—one by an Indian battalion, the other by the Royal Natal Carabineers—were repulsed. A third, larger attack at dawn on 13 October provided the Rhodesian Company of the Cape Town Highlanders with some of the fiercest combat they encountered in Italy. Advancing up the slope on the Allied right flank while being fired on from two directions, they suffered heavy casualties but achieved their objective and held it. Both Rhodesian artillery batteries provided support during the assault. When the line stabilised in November 1944, the portion occupied by the 6th Armoured Division extended for 16 kilometres (9.9 mi) along the heights over the Reno River.
In the mid-19th century, oil wells developed quickly in various parts of the world, though the title of the "first oil well" depends on the criteria. In 1846, a group of Russian Imperial engineers directed by Major Alexeyev of the Bakinskii Corps of Mining Engineers accidentally struck oil while hand-drilling with a primitive percussion rig in Bibi-Heybat, near Baku (now Azerbaijan), though they were not specifically searching for oil. In 1853, Ignacy Łukasiewicz, who discovered how to distill kerosene from seep crude oil and invented the modern kerosene lamp, hand-dug the first intentional well for commercial oil extraction in Bóbrka, Poland, to supply fuel for lighting (still operational as of 2025). A hand-dug well and another refinery followed in 1857 near Ploiești, Romania. Romania (then a vassal of the Ottoman Empire) was the first country in the world to have its annual crude oil output officially recorded in international statistics – 275 tonnes for 1857. In 1858, Georg Christian Konrad Hunäus found a significant amount of petroleum while drilling for lignite in Wietze, Germany. Wietze later provided about 80% of German consumption in the Wilhelmine Era. The production stopped in 1963, but Wietze has hosted a petroleum museum since 1970. Oil sands have been mined since the 18th century. In Wietze, natural asphalt/bitumen has been explored since the 18th century. Both in Pechelbronn as in Wietze, the coal industry dominated the petroleum technologies.
In the Hh pathway, CK1δ can phosphorylate Smothened (Smo) thereby enhancing its activity. Moreover, its additional role in this signaling pathways is still controversial. In fact, on one hand CK1δ can phosphorylate Cubitus interruptus activator (CiA) thereby avoiding its proteasomal degradation, while on the other hand CK1δ-mediated phosphorylation of Ci can increase its ubiquitination and its partial proteolysis into the repressive form of Ci (CiR). In the Hpo pathway, CK1δ can phosphorylate yes-associated protein (YAP), the down-stream co-activator of Hpo-responsive gene transcription on Ser-381, which influences its proteasomal degradation. Moreover, the Hpo signaling pathway seems to be related with both, Wnt signaling. and p53 regulation In presence of Wnt ligand, CKδ/ε can phosphorylate the key Wnt-effector Dishevelled (Dvl) which inhibits the β-catenin destruction complex finally resulting in a higher stability of β-catenin. Here, YAP/Tafazzin (TAZ) can bind Dvl and reducing its CK1δ-mediated phosphorylation. Additionally, β-catenin can be retained into the cytoplasm after binding to YAP, which results in lower transcription of Wnt-responsive genes.
=== Possible uses === While gliotoxin exposure at high concentrations shows cytotoxic effects via a multitude of different pathways, low-dose gliotoxin has been shown to have beneficial biological functions. Low-dose gliotoxin can exert antioxidant activities in the presence of the thioredoxin redox system that can counter the release of ROS in cells as a result of the electron transport chain (ETC) during cellular respiration. Moderate doses of gliotoxin have also been found to exhibit an anti-inflammatory effect in vivo due to the suppression of NF-κB activity by gliotoxin. Doses of gliotoxin less than 40 nM can also activate latent HIV-1 gene expression, serving as a diagnostic of HIV infection. Gliotoxin can activate HIV-1 expression by targeting (LARP7), which results in the release of active P-TEFb and the positive regulation of transcription of HIV proteins. Treatment of 20 nM gliotoxin reversed HIV-1 latency without interfering in the activation of CD4+ or CD8+ T-cells that are involved in the elimination of HIV-infected cells. While research on this possible gliotoxin use is in early stages, this provides a possible future direction for HIV diagnosis and treatment.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
Dihexa has been reported to activate hepatocyte growth factor/c-Met signaling in cell studies. This pathway is linked to synapse formation and neuronal remodeling. The exact molecular interactions are not fully understood.